Mersana is advancing its own pipeline of novel compounds, which were generated utilizing the Fleximer platform. Our compounds have the potential to address multiple oncology indications with potentially reduced development risk by linking Fleximer to agents that, to different degrees, have already shown proof-of-concept in the clinic.
We have two proprietary cancer candidates with significant commercial potential that are in, or nearing, clinical development, as well as additional programs in earlier stages of development. XMT-1001, our lead candidate, is a Fleximer-camptothecin conjugate.
XMT-1107 is a Fleximer-fumagillin analog conjugate.
